14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ENTA vs LBRX: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
LBRX Captures Overall Composite Edge (35.5 SELL vs 46.2 HOLD), While ENTA Leads 3–2 on Growth & Valuation Pillars
LBRX Overall Winner
6-Pillar Tally: ENTA 3 – 2 LBRX (1 Tie)
Matrix Metrics: ENTA 4 – 6 LBRX
As of Nov 16, 2026, LB Pharmaceuticals Inc (LBRX) captures the overall head-to-head institutional edge over Enanta Pharmaceuticals, Inc (ENTA) on higher Unified Composite conviction (35.5/100 SELL vs. 46.2/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Profitability & Quality), while ENTA wins 3–2 across the 6-pillar growth and valuation breakdown. ENTA trades at $10.79 (44.0x Forward P/E, -90.0% operating margin) versus LBRX at $43.04 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While ENTA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. LBRX 35.5/100 SELL), LBRX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -90.0% operating margin) and revenue trajectory (+0.0% vs. -21.6% YoY).
Technical & Structure Timing Caution: ENTA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0); meanwhile LBRX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ENTA vs LBRX. Trailing 12-month operating profitability (ENTA -90.0% vs LBRX 0.0%) and valuation multiples (ENTA 44.0x vs LBRX N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $1.4B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ ENTA vs LBRX Key Questions & Quantitative Answers
As of Nov 16, 2026, LB Pharmaceuticals Inc (LBRX) captures the overall head-to-head institutional edge over Enanta Pharmaceuticals, Inc (ENTA) on higher Unified Composite conviction (35.5/100 SELL vs. 46.2/100 HOLD) after splitting the core matrix 6–4 (led by Growth & Scale, Profitability & Quality), while ENTA wins 3–2 across the 6-pillar growth and valuation breakdown. ENTA trades at $10.79 (44.0x Forward P/E, -90.0% operating margin) versus LBRX at $43.04 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ENTA currently prints a higher short-term Unified Composite Score (46.2/100 HOLD vs. LBRX 35.5/100 SELL), LBRX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -90.0% operating margin) and revenue trajectory (+0.0% vs. -21.6% YoY). Technical & Structure Timing Caution: ENTA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 43.0); meanwhile LBRX trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 56.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
LBRX leads the Growth & Scale pillar: ENTA posts -21.6% YoY revenue growth and -66.2% YoY earnings growth on $65M TTM revenue (100.0% gross margin, -90.0% operating margin), compared with LBRX at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ENTA generates $65M in USD-normalized revenue versus N/A for LBRX. In operating R&D and SG&A reinvestment, ENTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LBRX.
ENTA screens cheaper on headline valuation multiples. ENTA trades at 44.0x Forward P/E, 44.0x Trailing P/E, N/M PEG, and 5.3x EV/Revenue (-56.6% FCF margin), whereas LBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ENTA (-70.1% ROE) versus LBRX (-38.8% ROE) capital efficiency.
In options market volatility and institutional positioning, ENTA carries 78.7% implied volatility (11th %ile, Compressed (<25th %ile)), a 0.31x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.89β · 58% Vol realized risk). By comparison, LBRX carries 138.8% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 62% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.